NEW YORK (GenomeWeb) – MDxHealth today reported that its fourth quarter revenues more than doubled year over year on a sharp rise in ConfirmMDx sales. 

The company said that total revenues increased to $3.4 million in the quarter, up from $1.6 million in Q4 2013. Revenues from the ConfirmMDx prostate cancer test rose to $2.4 million from $1.2 million as test volume increased 46 percent to more than 3,300 tests from 2,300 tests in the year-ago quarter. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.